Novartis Finland company information, Employees & Contact Information

Novartis in Slovenia receives national gold award for innovation Novartis

At the Bled Strategic Forum, Novartis calls for decisive action to improve European competitiveness Novartis

Novartis opens applications for BioCamp 2025 – A unique event for young talents Novartis

Past Winners Novartis

Novartis ranks first in 2024 Access to Medicine Index Novartis

"Engineers are, among other things, drivers for progress" Novartis

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline Novartis

Novartis in Slovenia and the University of Ljubljana sign strategic cooperation agreement Novartis

Biomarker research to help modernize care in multiple sclerosis Novartis

Research and development Novartis

Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront Novartis

Global Health disease area research at Novartis Novartis

Research disease areas Novartis

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer Novartis

Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD) Novartis

Coronavirus Novartis

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer Novartis

Corporate culture can't be pretended, and that's its charm Novartis

Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN) Novartis

Cardiovascular, renal and metabolic Novartis

Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline Novartis

Novartis Slovenia raises the flag for the first time for Disability Pride Month to raise awareness of the importance of an inclusive and diverse society Novartis

Managed access programs Novartis

Early careers Novartis

People and culture Novartis

Our commitment to ethical and responsible use of Artificial Intelligence (AI) Novartis

Novartis bolsters innovative medicines strategy and renal pipeline with agreement to acquire Chinook Therapeutics for USD 3.2bn upfront (USD 40 / share) Novartis

Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness Novartis

Sickle cell disease Novartis

Novartis access principles Novartis

Climate Novartis

BioCamp on advanced approaches to cancer treatment Novartis

Board of Directors Novartis

Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria Novartis

Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease Novartis

Steffen Lang, the Novartis Executive Committee member attends the Bled Strategic Forum Novartis

Robots speed the pace of modern drug discovery Novartis

Novartis to sell its Roche stake in a bilateral transaction to Roche Novartis

About Novartis

Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms Novartis

Faces behind Novartis Novartis

Novartis in Slovenia joins UNICEF Slovenia in raising awareness of mental health in children and adolescents Novartis

Novartis in Slovenia backs UNICEF Slovenia’s World Mental Health Day campaign Novartis

Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader Novartis

Painting a picture of my patients’ psoriasis Novartis

Novartis presents a donation of EUR 20,000 to Mengeš Primary School Novartis

Novartis Slovenia receives the Gold Award for Innovation in the Central Slovenia Region Novartis

Novartis in Slovenia named one of Slovenia's best innovators Novartis

Fifteen years of the Novartis Ride for Life™ Novartis

Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention Novartis

Living our five priorities Novartis

Novartis in Slovenia with the ''Take to the Heart'' campaign to address high cholesterol Novartis

Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice Novartis

Product sales Novartis

Novartis employees give back to their communities Novartis

Novartis rides for cancer Novartis

Novartis expands its biopharmaceutical manufacturing site in Singapore Novartis

Novartis CEO defends $12 billion deal for Avidity as 'appropriate risk to take' NewsX

Novartis nears $70-plus per share deal to acquire Avidity Biosciences, Bloomberg News reports NewsX

Novartis to acquire Avidity Biosciences for about $12 billion NewsX